Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy

Rivastigmine (Exelon®) for Treatment of Dementia in Patient With Progressive Supranuclear Paresis Open Label Phase 2 Study

to show that

1. patients improve and stabilize after 12 -24 week treatment with rivastigmine in memory function
2. use of rivastigmine has a positive effect on apathy in PSP patients
3. therapy with rivastigmine has a no positive benefit on speech and overall results of the MMST
4. changes in motor activity are associated with changes in language and overall results of the in MMST

Inclusion Criteria:

• diagnosis of PSP
• willingness to participate in the study
• informed consent
• ability to speak
• no further CNS diseases
• written informed consent
• stable state of health
• ability to give informed consent, will checked by an independent physician

Exclusion Criteria:

• alcohol abuses
• acute psychosis
• pregnancy or lactation
• known previous drug reaction or hypersensitivity of rivastigmine or other carbamate derivatives
• liver failure
• known sick sinus syndrome or excitation disturbance
• known ulcus ventriculi or duodenal ulcer
• known asthma or COPD
• seizures
• renal failure